Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lan Quach

Physician Assistant San Diego, CA Physician Assistant

NPI 1730462904 CMS profile 10449689

5060 Shoreham Pl Ste 100, San Diego, CA 92122

Open in the dashboard

General payments

$16,297

415 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lan Quach of San Diego, CA is reported in the CMS Open Payments database as having received $16,297 across 415 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,303 100
2024 General $3,509 96
2023 General $4,599 122
2022 General $2,396 56
2021 General $1,492 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lan Quach
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lan Quach were reported at $4,303. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lan Quach Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,492 $132 $37–$438 $132
2022 $2,396 $155 $48–$522 $149
2023 $4,599 $167 $52–$557 $160
2024 $3,509 $178 $55–$600 $164
2025 $4,303 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $2,396 36 payments
  2. Otsuka America Pharmaceutical, Inc. $2,003 37 payments
  3. AbbVie, Inc. $1,828 62 payments
  4. Axsome Therapeutics, Inc. $1,822 32 payments
  5. ITI, Inc. $1,751 43 payments
  6. Lundbeck LLC $1,451 69 payments
  7. Alkermes, Inc. $1,190 29 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $1,113 54 payments
  9. Janssen Pharmaceuticals, Inc $835 11 payments
  10. Teva Pharmaceuticals USA, Inc. $514 6 payments
  11. Other $1,396 36 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,120 410 payments
  2. Consulting Fee $115 1 payment
  3. Education $63 4 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $1,973 31 payments
  2. Auvelity $1,822 32 payments
  3. VRAYLAR $1,724 57 payments
  4. REXULTI Psychiatry $1,506 32 payments
  5. REXULTI Psychiatry $1,427 68 payments
  6. CAPLYTA $1,366 28 payments
  7. TRINTELLIX $1,113 54 payments
  8. LYBALVI Cns $1,073 27 payments
  9. LYBALVI Cns $778 11 payments
  10. LYBALVI Cns $732 9 payments
  11. Other $7,299 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

479

Median for Physician Assistant: 241

Drug cost

$265,895

Median for Physician Assistant: $4,110

Branded share of claims

37.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 96 $119,853
Austedo Xr Deutetrabenazine Brand 14 $111,362
Rexulti Brexpiprazole Brand 11 $18,096
Lurasidone Hcl Generic 11 $13,057
Trazodone Hcl Generic 43 $726
Duloxetine Hcl Generic 43 $592
Bupropion Xl Bupropion Hcl Brand 43 $391
Quetiapine Fumarate Generic 36 $380
Gabapentin Generic 35 $331
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 14 $271

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $417
  • Otsuka America Pharmaceutical, Inc. $246
$663 11 —
VRAYLAR
  • AbbVie, Inc. $512
$512 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $409
$409 — —
Auvelity
  • Axsome Therapeutics, Inc. $366
$366 — —
CAPLYTA
  • ITI, Inc. $299
$299 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record